Intravesical Gemcitabine for Superficial Bladder Carcinoma

The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.

[1]  A. Carcas,et al.  Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. , 2004, The Journal of urology.

[2]  C. Stoffregen,et al.  Immediate postoperative instillation of gemcitabine after transurethral resection of bladder tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Ferhat,et al.  Intravesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of bladder. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Peters,et al.  Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation , 2004, BJU international.

[5]  G. Peters,et al.  Intravesical gemcitabine: a phase 1 and pharmacokinetic study. , 2004, European urology.

[6]  O. Nativ,et al.  Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Russo,et al.  Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.